These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2966807)

  • 1. Peripheral blood lymphocytes from thermal injury patients are defective in their ability to generate lymphokine-activated killer (LAK) cell activity.
    Klimpel GR; Herndon DH; Stein MD
    J Clin Immunol; 1988 Jan; 8(1):14-22. PubMed ID: 2966807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective NK cell activity following thermal injury.
    Klimpel GR; Herndon DN; Fons M; Albrecht T; Asuncion MT; Chin R; Stein MD
    Clin Exp Immunol; 1986 Nov; 66(2):384-92. PubMed ID: 3493101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
    J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
    Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
    J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
    Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
    Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on cytotoxicity generated in human mixed lymphocyte culture. IV. Interleukin 2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes.
    Shau H; Gray JD; Golub SH
    Cancer Immunol Immunother; 1988; 27(3):255-60. PubMed ID: 2972366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
    Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
    Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
    Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
    Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocompetence of tissue infiltrating lymphocytes in bladder tumors.
    Tsujihashi H; Matsuda H; Uejima S; Akiyama T; Kurita T
    J Urol; 1988 Oct; 140(4):890-4. PubMed ID: 3262173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of serum immunosuppressive factors on the cytotoxicity of lymphokine-activated killer (LAK) cells induced by recombinant interleukin 2(R-IL2)].
    Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Kunii Y; Sakata K
    Nihon Geka Gakkai Zasshi; 1988 Jul; 89(7):992-8. PubMed ID: 2975748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer.
    Letessier EM; Sacchi M; Johnson JT; Herberman RB; Whiteside TL
    Cell Immunol; 1990 Oct; 130(2):446-58. PubMed ID: 2145080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood lymphocytes resistant to Epstein-Barr virus immortalization manifest high natural killer (NK) type activity against NK-resistant target cells.
    Gosselin J; Menezes J; Mercier G; Lamoureux G; Oth D
    Viral Immunol; 1990; 3(1):55-65. PubMed ID: 2153385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.
    Anderson PM; Bach FH; Ochoa AC
    Cancer Immunol Immunother; 1988; 27(1):82-8. PubMed ID: 3260824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The precursors and effectors of human lymphokine-activated killer (LAK) cells].
    Guo X
    Zhonghua Yi Xue Za Zhi; 1993 May; 73(5):266-9, 317-8. PubMed ID: 8221242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on adoptive immunotherapy using recombinant interleukin 2].
    Sugiyama Y; Takao H; Saji S; Sakata K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1307-13. PubMed ID: 3488028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.